Endovascular treatment of femoro-popliteal disease with the Supera stent: results of a multicenter study

Date Icon Publish Date
  • Giuseppe Guzzardi
    Department of Radiology, Unit of Interventional Radiology, “Maggiore della Carità” University Hospital, Novara, Italy.
  • Angelo Spinazzola
    Unit of Interventional Radiology, ASST-Crema, Crema, Italy.
  • Gianluca Cangiano
    Unit of Interventional Radiology, “A. Cardarelli” Hospital, Naples, Italy.
  • Massimiliano Natrella
    Department of Radiology, “G. Parini” Hospital, Aosta, Italy.
  • Andrea Paladini
    Department of Radiology, Unit of Interventional Radiology, “Maggiore della Carità” University Hospital, Novara, Italy.
  • Carla Porta
    Division of Vascular Surgery, “Maggiore della Carità” University Hospital, Novara, Italy.
  • Luca Boccalon
    Division of Vascular Surgery, ASST-Crema, Crema, Italy.
  • Davide Negroni
    Department of Radiology, Unit of Interventional Radiology, “Maggiore della Carità” University Hospital, Novara, Italy. https://orcid.org/0000-0002-1570-3695
  • Giovanni Leati
    Unit of Interventional Radiology, ASST-Crema, Crema, Italy.
  • Domenico Laganà
    Department of Experimental and Clinical Medicine, “Magna Graecia” University, Catanzaro, Italy.
  • Riccardo Guglielmi
    Istitute of Radiology, Spital Thurgau AG, Kantonsspital Münsterlingen, Switzerland.
  • Alessandro Carriero
    Department of Radiology, Unit of Interventional Radiology, “Maggiore della Carità” University Hospital, Novara, Italy.

ABSTRACT

Background: Even though many types of stents have been tested in superficial femoral artery (SFA) and popliteal artery (PA), the vast majority of these devices have provided an unsatisfactory outcome, probably due their unsuitable anatomical and physiological characteristics. The Supera peripheral stent (Abbott Vascular, Santa Rosa, CA, USA) is a braided interwoven nitinol device specifically designed for treating atherosclerotic lesions of the femoro-popliteal segment. The aim of this multicenter retrospective study was to describe the effectiveness of Supera stents in the management of femoral-popliteal atherosclerotic lesions and to critically analyze our findings in the context of current and past literature.

Design and Methods:
 In this study we enrolled only patients who satisfied the inclusion criteria: 1) patients affected by chronic obstructive arterial disease (COAD) grade II, as per Rutherford classification; 2) patients treated with endovascular revascularization and Supera stent implantation in the femoro-popliteal axis. We retrospectively analyzed the Doppler Ultra-sound (US) follow-up at 12-24 and 36 month in order to detect the vascular occlusions. The primary patency, primary patency assisted and TLR were described statistically analyzed by survival analysis and the demographic data, clinical data, device safety following stenting were described as frequency and mean value.

Results: 
105 endovascular procedures on 99 patients for femoro-popliteal stenting with Supera were performed in four Italian hospitals. The median follow-up was 39 months (range 6-72), with primary patency rate of 83.1%, 74.3% and 69.5% at 12, 24 and 36 months after the procedure. The primary patency assisted was 89.9%, 76.8% and 73.4% in the same period, while the freedom from TLR values were 92.7%, 91.5% and 89.5% at 12, 24 and 36 months after the procedure, respectively. The mortality rate recorded at 12 months from the Supera implantation was 2.8% (3 out of 99 patients enrolled).

Conclusions:
 Our data were in agreement with the current literature, showing the non-inferiority Supera stent in relation to the other stent available. Supera stent showed an excellent safety, effectiveness profile and high durability for the treatment of PAD patients with femoro-popliteal artery disease.

REFERENCES

1. Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007;12(3):223–34.
2. de Boer SW, van den Heuvel DAF, de Vries-Werson DAB, Vos JA, Fioole B, Vroegindeweij D, et al. Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions. J Endovasc Ther. 2017;24(6):783–92.
3. Chan YC, Cheng SW, Cheung GC. A midterm analysis of patients who received femoropoplitel helical interwoven nitinol stents. J Vasc Surg. 2019;
4. Gray WA, Feiring A, Cioppi M, Hibbard R, Gray B, Khatib Y, et al. S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes. J Vasc Interv Radiol [Internet]. 2015;26(1):21–8. Available from: http://dx.doi.org/10.1016/j.jvir.2014.09.018
5. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet [Internet]. 2013;382(9901):1329–40. Available from: http://dx.doi.org/10.1016/S0140-6736(13)61249-0
6. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12(1):6–12.
7. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: Twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18(5):613–23.
8. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-Eluting and Bare Nitinol Stents for the Treatment.pdf. 2006;701–10.
9. Rocha-Singh KJ, Bosiers M, Schultz G, Jaff MR, Mehta M, Matsumura JS. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. Catheter Cardiovasc Interv. 2015;86(1):164–70.
10. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–76.
11. Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg [Internet]. 2013;58(2):386-395.e4. Available from: http://dx.doi.org/10.1016/j.jvs.2013.01.050
12. San Norberto EM, Fuente R, Flota CM, Taylor JH, Vaquero C. Impact of Implantation Defects on Intermediate Outcome of Supera Stent for Popliteal Artery Stenosis. Ann Vasc Surg [Internet]. 2017;41:186–95. Available from: http://dx.doi.org/10.1016/j.avsg.2016.09.021
13. Maleckis K, Deegan P, Poulson W, Sievers C, Desyatova A, MacTaggart J, et al. Comparison of femoropopliteal artery stents under axial and radial compression, axial tension, bending, and torsion deformations. J Mech Behav Biomed Mater [Internet]. 2017;75(July):160–8. Available from: http://dx.doi.org/10.1016/j.jmbbm.2017.07.017
14. Jude S. Summary of Safety and Effectiveness Data ( Ssed ). US Food Drug Adm. 2016;39:1–30.
15. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American college of cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 135, Circulation. 2017. 726–779 p.
16. Brevetti G, Bucur R, Balbarini A, Melillo E, Novo S, Muratori I, et al. Women and peripheral arterial disease: Same disease, different issues. J Cardiovasc Med. 2008;9(4):382–8.
17. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185–91.
18. Poulson W, Kamenskiy A, Seas A, Deegan P, Lomneth C, MacTaggart J. Limb flexion-induced axial compression and bending in human femoropopliteal artery segments. J Vasc Surg [Internet]. 2018;67(2):607–13. Available from: http://dx.doi.org/10.1016/j.jvs.2017.01.071
19. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines – Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology. J Vasc Surg [Internet]. 2011;54(5):e32–58. Available from: http://dx.doi.org/10.1016/j.jvs.2011.09.001
20. Gökgöl C, Schumann S, Diehm N, Zheng G, Büchler P. In Vivo Quantification of the Deformations of the Femoropopliteal Segment. J Endovasc Ther. 2017;24(1):27–34.
21. Patel SD, Zymvragoudakis V, Sheehan L, Lea T, Modarai B, Katsanos K, et al. Atherosclerotic Plaque Analysis: A Pilot Study to Assess a Novel Tool to Predict Outcome Following Lower Limb Endovascular Intervention. Eur J Vasc Endovasc Surg [Internet]. 2015;50(4):487–93. Available from: http://dx.doi.org/10.1016/j.ejvs.2015.05.006
22. Bhatt H, Kovach R, Janzer S, George JC. SUPERA stent outcomes in Above-The-Knee IntervEntions: Effects of COMPression and ELongation (SAKE-COMPEL) Sub-study. Cardiovasc Revascularization Med [Internet]. 2018;19(5):512–5. Available from: https://doi.org/10.1016/j.carrev.2017.11.007
23. Garcia LA, Rosenfield KR, Metzger CD, Zidar F, Pershad A, Popma JJ, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89(7):1259–67.
24. Sibé M, Kaladji A, Boirat C, Cardon A, Chaufour X, Bossavy JP, et al. French multicenter experience with the GORE TIGRIS Vascular Stent in superficial femoral and popliteal arteries. J Vasc Surg [Internet]. 2017;65(5):1329–35. Available from: http://dx.doi.org/10.1016/j.jvs.2016.11.056
25. Garcia L, Jaff MR, Metzger C, Sedillo G, Pershad A, Zidar F, et al. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015;8(5):1–8.
26. Scheinert D, Grummt L, Piorkowski M, Sax J, Scheinert S, Ulrich M, et al. A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-Month results of the SUPERA SFA registry. J Endovasc Ther. 2011;18(6):745–52.
27. Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392(10157):1541–51.
28. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016;133(15):1472–83.
29. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the resilient randomized trial. J Endovasc Ther. 2012;19(1):1–9.
30. Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, et al. The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protégé everflex nitinol stent system II (DURABILITY II). J Vasc Surg [Internet]. 2013;58(1):73-83.e1. Available from: http://dx.doi.org/10.1016/j.jvs.2012.12.066
31. Ohki T, Kichikawa K, Yokoi H, Uematsu M, Yamaoka T, Maeda K, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg [Internet]. 2017;66(1):130-142.e1. Available from: http://dx.doi.org/10.1016/j.jvs.2017.01.065
32. Palena LM, Diaz-Sandoval LJ, Sultato E, Brigato C, Candeo A, Brocco E, et al. Feasibility and 1-Year outcomes of subintimal revascularization with supera® stenting of long femoropopliteal occlusions in critical limb ischemia: The “Supersub” Study. Catheter Cardiovasc Interv. 2017;89(5):910–20.
33. Armstrong EJ, Jeon-Slaughter H, Kahlon RS, Niazi KA, Shammas NW, Banerjee S. Comparative Outcomes of Supera Interwoven Nitinol vs Bare Nitinol Stents for the Treatment of Femoropopliteal Disease: Insights From the XLPAD Registry. J Endovasc Ther. 2020;27(1):60–5.
Our most popular topics on Journal of Public Health Research

Leave a Reply

Your email address will not be published.